ArticleFrontiers in medicine2025
A population-based registry study on psoriasis-associated burden of disease in Finland.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite advancements in treatment, unmet needs persist for patients with plaque psoriasis (PSO). This study characterized PSO patients who were initiating or switching biologic medications, with or without prior biologic use, and highlighted the unmet needs due to medication switches and concomitant treatments. The impact of biologic therapy initiation was assessed through changes in healthcare resource utilization (HCRU), sick leave, and disability pensions. Methods: This study utilized electronic healthcare data of adult patients with PSO and reimbursed biologic medication purchases made between 2013 and 2021 in Finland. Patients were followed from the day of first biologic treatment purchase (first biological cohort) or switch (switchers) until 2022 or death/loss of follow-up. Results: A total of 2,437 patients with PSO and biologic medication purchases were investigated. Of this total, 14.2% ( Discussion: This study highlights the need for timely treatment and underscores the significant unmet needs among patients with PSO. Further studies are needed to evaluate the overall benefits of early utilization of highly effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.